Skip to main content

Atrophy

6
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Shionogi
ShionogiJapan - Osaka
5 programs
5
OspemifenePhase 31 trial
Ospemifene 30 mgPhase 31 trial
Ospemifene 60 mgPhase 31 trial
Ospemifene 60 mgPhase 31 trial
Ospemifene 60Mg Oral TabletPhase 31 trial
Active Trials
NCT01585558Completed180Est. Sep 2008
NCT00276094Completed826Est. Dec 2007
NCT00566982Completed426Est. Jul 2009
+2 more trials
Peptonic Medical
Peptonic MedicalSweden - Stockholm
1 program
1
OxytocinPhase 2
Galderma
GaldermaTX - Dallas
1 program
Macrolane VRF 30N/A1 trial
Active Trials
NCT00931268Completed10Est. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ShionogiOspemifene 60 mg
ShionogiOspemifene 60 mg
ShionogiOspemifene
ShionogiOspemifene 60Mg Oral Tablet
ShionogiOspemifene 30 mg
GaldermaMacrolane VRF 30

Clinical Trials (6)

Total enrollment: 2,662 patients across 6 trials

NCT00729469ShionogiOspemifene 60 mg

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Start: Jul 2008Est. completion: Aug 2009919 patients
Phase 3Completed
NCT00566982ShionogiOspemifene 60 mg

A Clinical Study to Evaluate the Safety of Ospemifene

Start: Oct 2007Est. completion: Jul 2009426 patients
Phase 3Completed
NCT01585558ShionogiOspemifene

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Start: May 2006Est. completion: Sep 2008180 patients
Phase 3Completed
NCT01586364ShionogiOspemifene 60Mg Oral Tablet

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Start: May 2006Est. completion: Dec 2008301 patients
Phase 3Completed
NCT00276094ShionogiOspemifene 30 mg

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Start: Jan 2006Est. completion: Dec 2007826 patients
Phase 3Completed
NCT00931268GaldermaMacrolane VRF 30

Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane

Start: Aug 2009Est. completion: May 201210 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.